CRISPR Therapeutics AG (CRSP)
| Market Cap | 7.40B |
| Revenue (ttm) | 901.76M |
| Net Income (ttm) | 446.58M |
| Shares Out | 76.20M |
| EPS (ttm) | 5.90 |
| PE Ratio | 16.19 |
| Forward PE | 23.36 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,325,471 |
| Open | 96.95 |
| Previous Close | 97.06 |
| Day's Range | 94.25 - 97.65 |
| 52-Week Range | 84.38 - 220.20 |
| Beta | 2.25 |
| Analysts | Buy |
| Price Target | 159.05 (+66.4%) |
| Est. Earnings Date | Oct 28, 2021 |
About CRSP
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate...
Financial Performance
Financial StatementsAnalyst Forecast
According to 18 analysts, the average rating for CRSP stock is "Buy." The 12-month stock price forecast is 159.05, which is an increase of 66.44% from the latest price.
News
Earnings Preview: CRISPR Therapeutics AG (CRSP) Q3 Earnings Expected to Decline
CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Things About CRISPR Therapeutics That Smart Investors Know
The company's value isn't reflected in typical performance metrics.
3 Beaten-Down Stocks Cathie Wood Is Buying That Wall Street Thinks Will Skyrocket
These growth stocks could rebound in a big way.
2 Top Healthcare Stocks That Could Be Bought Out in 2022
These two novel-drug makers could be top takeover targets next year.
4 Biotechs to Watch Amid Rising Prominence of Gene Therapies
Here we discuss four biotech companies, CRSP, EDIT, SRPT and BEAM, that have the potential to gain from their promising gene therapy pipeline candidates.
CRISPR Therapeutics Announces Transition of Chief Financial Officer
ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serio...
CRISPR price outlook: RBC sees upside to $117
Shares of CRISPR Therapeutics AG (NASDAQ: CRSP) fell just under 10% on Wednesday as the biotech firm presented updated data for the phase 1 trial of its blood cancer candidate CTX 110. RBC Capital main...
CRSP Stock: The Cancer Study News Sending Crispr Therapeutics Lower Today
Crispr Therapeutics (CRSP) stock is falling on Wednesday following the release of new results from a Phase 1 clinical trial. The post CRSP Stock: The Cancer Study News Sending Crispr Therapeutics Lower ...
Why CRISPR Therapeutics Stock Is Sinking Today
Investors aren't impressed with the early-stage results from the biotech's lead cancer therapy candidate.
Why CRISPR Therapeutics Stock Is Tumbling Today
CRISPR Therapeutics AG (NASDAQ: CRSP) is trading lower Wednesday after the company reported results from its Phase 1 CARBON trial of CTX110 in relapsed or refractory CD19+ B-cell malignancies. “We are e...
Will CRISPR Stock Rebound After A 17% Fall In A Month?
The stock price of CRISPR Therapeutics, a biotechnology gene editing company focused on developing gene-based medicines for human diseases, reached an all-time high of $210 in January of this year befor...
How to Invest in Biotech Stocks in a Bear Market
Hint: it doesn't really matter what kind of market it is.
CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+...
-58% overall response rate (ORR) and 38% complete response (CR) rate in large B-cell lymphoma (LBCL) with a single dose of CTX110 at Dose Level 2 (DL2) and above on an intent-to-treat (ITT) basis-
Why CRISPR Therapeutics (CRSP) Stock is Falling Today
Shares of leading gene editing company CRISPR Therapeutics (CRSP) are sliding on Friday. What's behind the slump?
Why CRISPR Therapeutics Stock Fell 10.4% Last Month
CRISPR Therapeutics stock is now down roughly 33% across 2021's trading.
CRISPR Therapeutics to Host Virtual Event Highlighting CTX110™ Clinical Data
-Management to host conference call and webcast on October 12th at 4:30 p.m. ET-
CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $111.93, marking a +1.57% move from the previous day.
3 Biotech Stocks Wall Street Thinks Could Rise 44% or Better
A stock market that soured on biotech stocks in general is presenting some bargain opportunities.
4 Stocks Expected to Increase Sales 25,750% to 2,970,000% in 5 Years
These companies could deliver jaw-dropping revenue growth through mid-decade.
Here's Why Editas Stock Dropped After Data From CRISPR-Based Retinal Disorder Candidate
Editas Medicine Inc (NASDAQ: EDIT) has announced initial clinical data from the ongoing Phase 1/2 BRILLIANCE trial of EDIT-101 for blindness due to Leber congenital amaurosis 10 (LCA10), a CEP290-relate...
These 3 Top Healthcare Stocks Are Screaming Buys Right Now
If the market crashes these companies could be insulated.
7 Cathie Wood Stocks Every Growth Investor Needs In Their Portfolio
These top seven stocks among Cathie Wood's top holdings are ones investors may be enticed to consider right now. The post 7 Cathie Wood Stocks Every Growth Investor Needs In Their Portfolio appeared fir...
CRISPR Therapeutics to Participate in the Chardan's 5th Annual Genetic Medicines Conference
ZUG, Switzerland and CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for seri...
Why Cathie Wood Is Buying 2 Gene-Editing Stocks but Selling Another
Wood is following an important strategy with gene-editing stocks.
CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should Know
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $117.81, moving +0.48% from the previous trading session.